AstraZeneca to supply Europe with up to 400 million doses of COVID-19 vaccine
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
List view / Grid view
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
Bayer will acquire KaNDy Therapeutics Ltd for an upfront cost of $425 million to expand its drug development pipeline in women’s healthcare.
After "allegations of wrongdoing" were connected to Eastman Kodak Company following a $765 million loan from the US government, a review has been announced.
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
A new report has outlined that AstraZeneca has been granted protection from product liability claims regarding its COVID-19 vaccine candidate.
Pfizer is to manufacture and supply the investigational COVID-19 treatment remdesivir for Gilead Sciences at one of its facilities.
According to David Bennett, securing and building trust in the label, brand and process of a highly regulated industry player in a complex age will demand a new approach.
Abingdon Health's COVID-19 rapid antibody test has been registered with the UK's Medicines and Healthcare products Regulatory Agency.
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
The European Commission has granted marketing authorisation to Celltrion's Remsima (infliximab, CT-P13) subcutaneous formulation.
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
The CEO of PQE Group has formed a task force of employees in the corporate community to research and dispel fake news regarding COVID-19.
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to make the bulk drug substance for NVX-CoV2373, the Novavax COVID-19 vaccine candidate.
The FDA is requiring that labels for opioid pain medicine and medicines to treat opioid use disorder recommend healthcare professionals discuss the availability of naloxone with patients to reduce overdoses.
Does expert knowledge on COVID-19 need to be more accessible across the globe? This article explores this issue and addresses how greater accessibility could help fight the pandemic in emerging countries.